Opioid Induced Constipation Clinical Trial
Official title:
A Phase I, Randomised, Open-label, 3 Way Cross-over Study in Healthy Volunteers to Demonstrate the Bioequivalence of the Naloxegol 25 mg Commercial and Phase III Formulations and to Assess the Effect of Food Administration on the Pharmacokinetics of the Commercial Formulation.
The purpose of this study is to demonstrate the Bioequivalence, assess food administration on the Pharmacokinetics with naloxegol.
A Phase I, Randomised, Open-label, 3 way Cross-over Study in Healthy Volunteers to Demonstrate the Bioequivalence of the Naloxegol 25 mg Commercial and Phase III Formulations and to Assess the Effect of Food Administration on the Pharmacokinetics of the Commercial Formulation. ;
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT02813369 -
Naloxegol Health Outcome Post Authorisation Safety Study
|
||
| Completed |
NCT01957046 -
A Single-arm, Study to Assess the Effect and Tolerability of Standardised Laxative Therapy (SLT) for the Reversal of Opioid-induced Constipation (OIC).
|
Phase 4 | |
| Completed |
NCT01401985 -
A Study of TD-1211 in Subjects With Opioid-Induced Constipation (OIC)
|
Phase 2 | |
| Completed |
NCT00984334 -
Naloxone SR Capsules in Patients With Opioid Induced Constipation
|
Phase 2 | |
| Completed |
NCT01207427 -
Evaluation of the Efficacy and Safety of ADL5945 for the Treatment of Opioid-induced Constipation in Adults Taking Opioid Therapy for Chronic Noncancer Pain
|
Phase 2 | |
| Completed |
NCT01459926 -
A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of TD-1211 in Subjects With Opioid-Induced Constipation
|
Phase 2 | |
| Terminated |
NCT01117051 -
Prucalopride Effects on Subjects With Chronic Non-cancer Pain Suffering From Opioid Induced Constipation
|
Phase 3 | |
| Completed |
NCT03060512 -
To Evaluate Patient Preference of Movantik and Polyethylene Glycol 3350 for Opioid Induced Constipation
|
Phase 4 | |
| Completed |
NCT01109511 -
A Comparison of Oxycodone/Naloxone and Oxycodone After Laparoscopic Hysterectomy
|
Phase 4 | |
| Active, not recruiting |
NCT02813356 -
Naloxegol US PMR CV Safety.
|
||
| Completed |
NCT01812733 -
Non-interventional Study Comparing Targiniq and Oxycodone/Laxatives
|
N/A | |
| Completed |
NCT02813148 -
Naloxegol Drug Utilization Post Authorisation Safety Study
|
||
| Completed |
NCT01443403 -
A Study of S-297995 for the Treatment of Opioid-Induced Constipation in Subjects With Non-Malignant Chronic Pain Receiving Opioid Therapy
|
Phase 2 | |
| Completed |
NCT03638440 -
Real World Observational Study of Naloxegol for Patients With Cancer Pain Diagnosed With OIC.
|